A carregar...
Second-line treatment options in hepatocellular carcinoma
For many years, sorafenib has been the only approved systemic treatment for advanced hepatocellular carcinoma (HCC). For over a decade, randomized controlled trials exploring the efficacy of new drugs both in first- and second-line treatment have failed to prove any survival benefit. However, in the...
Na minha lista:
| Publicado no: | Drugs Context |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioExcel Publishing Ltd
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6469745/ https://ncbi.nlm.nih.gov/pubmed/31024634 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.212577 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|